WEST HOLLYWOOD, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- #" Designer Guilherme Wentz In His Studio Designer Guilherme Wentz In His Studio
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable 1-04-2025, 00:00